single center non-randomized clinical trial of efficacy and safety of cidofovir for adenovirus infection after hematopoietic stem cell transplantation

single center non-randomized clinical trial of efficacy and safety of cidofovir for adenovirus infection after hematopoietic stem cell transplantation - a clinical trial of efficacy and safety of cidofovir for adenovirus infection after hematopoietic stem cell transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029434

Enrollment

Registered

2017-10-05

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

adenovirus infection after hematopoietic stem cell transplantation

Interventions

Cidofovir 1mg/kg/day is administrated intravenously three times a week. Injection week and drug dose is adjusted depending on patient condition. Pharmakokinetics of cidofovir is measured.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients who have received hematopoietic stem cell transplantation 2. patients with adenovirus infection 3. patients with risk of adenovirus infection 4. patients who agree in writing

Exclusion criteria

Exclusion criteria: 1. patients with allergy to cifofovir 2. patients who are recognized as inadaptable for this trial

Design outcomes

Primary

Measure	Time frame
virological response after treatment	—

Secondary

Measure	Time frame
1. side effect of cidofovir 2. pharmakokinetics of cidofovir	—

Countries

Japan

Contacts

Public ContactKatsuji Kaida

Hyogo college of medicine Department of hematology

kaidak@hyo-med.ac.jp0798-45-6886

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026